Bluefin Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,500
| Closed | -$224K | – | 253 |
|
|
2023
Q3 | $224K | Sell |
1,500
-1,900
| -56% | -$279K | 0.02% | 95 |
|
|
2023
Q2 | $458K | Buy |
+3,400
| New | +$499K | 0.09% | 61 |
|
|
2023
Q1 | – | Sell |
-8,340
| Closed | -$1.35M | – | 232 |
|
|
2022
Q4 | $1.35M | Sell |
8,340
-1,870
| -18% | -$287K | 0.2% | 74 |
|
|
2022
Q3 | $1.37M | Sell |
10,210
-1,440
| -12% | -$207K | 0.12% | 108 |
|
|
2022
Q2 | $1.8M | Buy |
11,650
+4,390
| +60% | +$671K | 0.2% | 81 |
|
|
2022
Q1 | $1.18M | Sell |
7,260
-13,297
| -65% | -$1.93M | 0.11% | 110 |
|
|
2021
Q4 | $2.78M | Sell |
20,557
-12,235
| -37% | -$1.45M | 0.19% | 93 |
|
|
2021
Q3 | $3.54M | Buy |
32,792
+11,134
| +51% | +$1.27M | 0.35% | 53 |
|
|
2021
Q2 | $2.44M | Buy |
21,658
+5,807
| +37% | +$654K | 0.16% | 99 |
|
|
2021
Q1 | $1.72M | Buy |
15,851
+3,528
| +29% | +$377K | 0.08% | 126 |
|
|
2020
Q4 | $1.32M | Buy |
+12,323
| New | +$1.18M | 0.08% | 159 |
|
|
2020
Q3 | – | Sell |
-2,875
| Closed | -$271K | – | 78 |
|
|
2020
Q2 | $282K | Sell |
2,875
-174,564
| -98% | -$15.4M | 0.02% | 195 |
|
|
2020
Q1 | $13.5M | Buy |
177,439
+93,595
| +112% | +$7.97M | 1.74% | 10 |
|
|
2019
Q4 | $7.42M | Buy |
83,844
+21,710
| +35% | +$1.8M | 0.49% | 52 |
|
|
2019
Q3 | $4.71M | Buy |
+62,134
| New | +$4.26M | 0.68% | 26 |
|
|
2019
Q1 | – | Sell |
-2,200
| Closed | -$180K | – | 393 |
|
|
2018
Q4 | $203K | Sell |
2,200
-16,866
| -88% | -$1.48M | 0.02% | 232 |
|
|
2018
Q3 | $1.8M | Buy |
+19,066
| New | +$1.81M | 0.17% | 117 |
|
|
2018
Q1 | – | Sell |
-7,960
| Closed | -$770K | – | 411 |
|
|
2017
Q4 | $770K | Buy |
7,960
+410
| +5% | +$38.6K | 0.05% | 194 |
|
|
2017
Q3 | $671K | Buy |
+7,550
| New | +$575K | 0.08% | 186 |
|
|
2016
Q4 | – | Sell |
-7,183
| Closed | -$453K | – | 528 |
|
|
2016
Q3 | $453K | Sell |
7,183
-4,754
| -40% | -$308K | 0.02% | 201 |
|
|
2016
Q2 | $739K | Sell |
11,937
-698
| -6% | -$42.5K | 0.07% | 165 |
|
|
2016
Q1 | $722K | Sell |
12,635
-7,292
| -37% | -$406K | 0.07% | 156 |
|
|
2015
Q4 | $1.18M | Buy |
19,927
+1,613
| +9% | +$92.9K | 0.09% | 209 |
|
|
2015
Q3 | $996K | Buy |
18,314
+10,486
| +134% | +$683K | 0.06% | 195 |
|
|
2015
Q2 | $526K | Buy |
+7,828
| New | +$511K | 0.03% | 291 |
|
|
2015
Q1 | – | Sell |
-7,399
| Closed | -$484K | – | 403 |
|
|
2014
Q4 | $484K | Buy |
7,399
+3,225
| +77% | +$203K | 0.03% | 357 |
|
|
2014
Q3 | $241K | Buy |
+4,174
| New | +$232K | 0.01% | 541 |
|
|
2013
Q3 | – | Sell |
-6,183
| Closed | -$300K | – | 412 |
|
|
2013
Q2 | $300K | Buy |
+6,183
| New | +$270K | 0.03% | 369 |
|
Other funds holding ABBV
Bluefin Capital Management's ABBV Position: Q4 2023 in Review
Bluefin Capital Management sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 1,500 shares — an estimated $224K sold.
Bluefin Capital Management first reported a position in ABBV in Q2 2013 and held it in 28 quarters. The position peaked at $13.5M in Q1 2020. 3,323 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.
- Bluefin Capital Management reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
- Bluefin Capital Management sold 1,500 AbbVie shares in Q4 2023, an estimated $224K.
- Bluefin Capital Management first reported a position in AbbVie in Q2 2013 and held it in 28 quarters.
- Bluefin Capital Management's AbbVie position peaked at $13.5M in Q1 2020.
- 3,323 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.
Based on Bluefin Capital Management's 13F filing for Q4 2023, filed 16 Feb 2024.